Related Experiment Video
Updated: Apr 7, 2026
06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
2.2K
Positioning Therapy for Ulcerative Colitis
Ari Grinspan1, Asher Kornbluth
1The Henry D. Janowitz Division of Gastroenterology, The Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, NY, 10029, USA, arigrinspan@gmail.com.
Current Gastroenterology Reports
|July 6, 2015
Summary
New ulcerative colitis (UC) therapies offer more options but pose challenges. This review positions emerging treatments like budesonide-MMX, adalimumab, golimumab, and vedolizumab within UC treatment algorithms.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Ulcerative colitis (UC) is a chronic inflammatory colon disease.
- Current treatments include mesalamine, steroids, thiopurines, and anti-TNF-α antibodies.
- Recent advancements have introduced novel therapeutic agents and treatment strategies.
Purpose of the Study:
- To review emerging therapies for ulcerative colitis.
- To discuss the optimal positioning of new agents within UC treatment algorithms.
- To address the challenges posed by new treatment options for clinicians.
Main Methods:
- Review of recent randomized controlled trials and clinical data.
- Analysis of novel ulcerative colitis therapies including budesonide-MMX, adalimumab, golimumab, and vedolizumab.
- Evaluation of combination therapies (infliximab and azathioprine) and comparative trials (infliximab vs. cyclosporine).
Main Results:
- Emerging agents provide new therapeutic avenues for UC management.
- Specific agents like budesonide-MMX, adalimumab, golimumab, and vedolizumab represent significant advancements.
- Combination and comparative trial data inform treatment decisions for refractory UC.
Conclusions:
- Optimal placement of new UC therapies requires careful consideration of individual patient factors and disease course.
- The evolving landscape of UC treatment necessitates updated clinical algorithms.
- Further research will refine the role of these novel agents in managing ulcerative colitis.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
654
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
654
01:21Inflammatory Bowel Disease V: Surgical Management
870
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
870
01:21Drugs for Treatment of Constipation-Predominant IBS
1.3K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.3K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
967
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
967
01:26Peptic Ulcer Disease IV: Management
663
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
663
01:17Drugs for Treatment of Diarrhea-Predominant IBS
903
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
903